检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.

Sunkyu Kim,Ralph Tiedt,Alice Loo,Thomas Horn,Scott Delach,Steven Kovats,Kristy Haas, Barbara Schacher Engstler,Alexander Cao,Maria Pinzon-Ortiz,Iain Mulford,Michael G Acker,Rajiv Chopra,Christopher Brain,Emmanuelle di Tomaso,William R Sellers,Giordano Caponigro

Oncotarget（2020）

引用 50|浏览69
暂无评分
摘要
[This corrects the article DOI: 10.18632/oncotarget.26215.].
更多
查看译文
关键词
CDK4/6 inhibitor,LEE011,preclinical,ribociclib,selectivity
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要